Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 3, 2015

Sartorius Opens New York Demonstration Lab

A new demonstration facility in New York gives Sartorius’ customers hands-on access to bioprocessing systems and lab instruments.

 

Sartorius has opened its first North American demonstration laboratory in Bohemia, NY to provide customers with access to the company’s upstream and downstream processing systems and laboratory products. The laboratory, part of the company’s new 40,000-sq-ft facility, features hands-on demonstration stations, as well as classroom learning space.

The Long Island-based Sartorius Application Center is modeled after similar application centers in China and Germany. In the FlexLab, customer can view FlexAct systems, Sartocheck bag testers, and TAP Biosystems equipment. Laboratory products on display include scales, balances, and liquid handling systems. In addition, an R&D section showed developments in bioreactors and freeze/thaw equipment.

At a grand opening event on June 2, Sartorius hosted customers, employees, the media, and local government officials for a ribbon-cutting ceremony and facility tours with introductions provided by Mary Lavin, the company’s president for North America.

Source: Sartorius

 


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.